lysophosphatidic acid has been researched along with Scleroderma, Systemic in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Kajiyama, H; Kakinuma, H; Kamigaso, S; Kobayashi, Y; Kuroda, S; Matsuda, D; Nakano, K; Naruse, T; Okumura-Kitajima, L; Toki, H; Tokura, S; Uneuchi, F; Wada, R; Yamagishi, J; Yonemoto, Y | 1 |
| Valentine, WJ; Yanagida, K | 1 |
| Amin, MA; Campbell, P; Fox, DA; Haak, AJ; Khanna, D; Larsen, SD; Neubig, RR; Ruth, JH; Tsou, PS | 1 |
| Bain, G; Black, KE; Castelino, FV; George, L; Goulet, L; Lafyatis, R; Pace, VA; Probst, CK; Tager, AM | 1 |
| Carbone, LD; Kikuchi, M; Morishige, J; Postlethwaite, A; Tokumura, A; Watsky, MA; Yoshioka, Y | 1 |
| Pattanaik, D; Postlethwaite, AE | 1 |
| Bolen, AL; Carbone, LD; Gotoh, M; Murakami-Murofushi, K; Postlethwaite, A; Tigyi, GJ; Watsky, MA; Yin, Z | 1 |
2 review(s) available for lysophosphatidic acid and Scleroderma, Systemic
| Article | Year |
|---|---|
Druggable Lysophospholipid Signaling Pathways.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Lysophospholipids; Molecular Targeted Therapy; Receptors, Lysophosphatidic Acid; Scleroderma, Systemic; Signal Transduction | 2020 |
A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis.
Topics: Autoimmunity; Blood Vessels; Fibrosis; Humans; Lysophospholipids; Scleroderma, Systemic; Sphingosine | 2010 |
5 other study(ies) available for lysophosphatidic acid and Scleroderma, Systemic
| Article | Year |
|---|---|
Lead generation from N-[benzyl(4-phenylbutyl)carbamoyl]amino acid as a novel LPA
Topics: Amino Acids; Animals; Fibrosis; Lysophospholipids; Mice; Scleroderma, Systemic | 2023 |
Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury.
Topics: Animals; Cell Culture Techniques; Cell Proliferation; Collagen Type I; Connective Tissue Growth Factor; Disease Models, Animal; DNA-Binding Proteins; Female; Humans; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Middle Aged; Myofibroblasts; NIH 3T3 Cells; Nipecotic Acids; Oncogene Proteins, Fusion; Scleroderma, Systemic; Serum Response Factor; Trans-Activators; Transcription, Genetic; Transforming Growth Factor beta | 2014 |
An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
Topics: Animals; Benzoates; Bleomycin; Case-Control Studies; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Fibroblasts; Fibrosis; Humans; Immunohistochemistry; Interleukin-6; Lysophospholipids; Mice; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Scleroderma, Systemic; Skin | 2016 |
Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis.
Topics: Adult; Case-Control Studies; Female; Humans; Lysophospholipids; Middle Aged; Phosphoric Diester Hydrolases; Scleroderma, Systemic; Sphingosine; Young Adult | 2009 |
Lysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblasts.
Topics: Actins; Adult; Analysis of Variance; Case-Control Studies; Cells, Cultured; Chlorides; Female; Fibroblasts; Humans; Lysophospholipids; Male; Middle Aged; Muscle, Smooth; Myofibroblasts; Scleroderma, Systemic; Skin | 2010 |